However, recent clinical trials - CodeBreaK100 [16] and KRYSTAL-1 [17] - have shown that sotorasib and adagrasib, two novel selective inhibitors of KRAS^G12C, demonstrate clinical efficacy with an acceptable adverse event profile in treating advanced NSCLC patients harboring this mutation. This evidence concerns the gene KRAS and non-small cell lung carcinoma.